Patents by Inventor Lawrence Nathan Tumey

Lawrence Nathan Tumey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF
    Publication number: 20230357417
    Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).
    Type: Application
    Filed: March 8, 2023
    Publication date: November 9, 2023
    Applicant: Pfizer Inc.
    Inventors: Manoj Baburao CHARATI, Yoon-Chi HAN, Madan KATRAGADDA, Nicole Melissa PICHÉ-NICHOLAS, Lawrence Nathan TUMEY
  • Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
    Patent number: 11613581
    Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 28, 2023
    Assignee: Pfizer, Inc.
    Inventors: Manoj Baburao Charati, Yoon-Chi Han, Madan Katragadda, Nicole Melissa Piché-Nicholas, Lawrence Nathan Tumey
  • Cysteine engineered antibody drug conjugates
    Patent number: 11364303
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise an engineered cysteine for site-specific conjugation.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 21, 2022
    Assignee: Pfizer Inc.
    Inventors: Madan Katragadda, Russell Dushin, Lawrence Nathan Tumey
  • ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF
    Publication number: 20200283536
    Abstract: The present invention provides antibodies that specifically bind to CD123. The invention further relates to immunoconjugates (e.g., antibody-drug conjugates, or ADCs) comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and ADCs for the treatment of a condition associated with cells expressing CD123 (e.g., cancer or autoimmune disease).
    Type: Application
    Filed: October 16, 2018
    Publication date: September 10, 2020
    Applicant: Pfizer Inc.
    Inventors: Manoj Baburao CHARATI, Yoon-Chi HAN, Madan KATRAGADDA, Nicole Melissa PICHÉ-NICHOLAS, Lawrence Nathan TUMEY
  • ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION
    Publication number: 20200069764
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.
    Type: Application
    Filed: November 19, 2019
    Publication date: March 5, 2020
    Applicant: Pfizer Inc.
    Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
  • CYSTEINE ENGINEERED ANTIBODY DRUG CONJUGATES
    Publication number: 20190099499
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise an engineered cysteine for site-specific conjugation.
    Type: Application
    Filed: September 24, 2018
    Publication date: April 4, 2019
    Inventors: Madan Katragadda, Russell Dushin, Lawrence Nathan Tumey
  • ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION
    Publication number: 20170216452
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.
    Type: Application
    Filed: November 21, 2016
    Publication date: August 3, 2017
    Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
  • Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
    Patent number: 7981912
    Abstract: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: July 19, 2011
    Assignee: Wyeth LLC
    Inventors: Youssef L. Bennani, Lawrence Nathan Tumey, Elizabeth Ann Gleason, Michael Joseph Robarge
  • BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF
    Publication number: 20110105573
    Abstract: The invention relates to benzimidazole acetic acid compounds which function as antagonists of the Chemoattractant Receptor-homologous molecule expressed on T-Helper type 2 cells (CRTH2) receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
    Type: Application
    Filed: June 8, 2010
    Publication date: May 5, 2011
    Inventors: Youssef L. Bennani, Lawrence Nathan Tumey, Elizabeth Ann Gleason, Michael Joseph Robarge
  • Substituted 3-cyanopyridines as protein kinase inhibitors
    Patent number: 7781591
    Abstract: The present teachings provide compounds of formula I and their pharmaceutically acceptable salts, hydrates, and esters, wherein R1, R2, and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: August 24, 2010
    Assignee: Wyeth LLC
    Inventors: Derek Cecil Cole, Diane Harris Boschelli, Yanong Daniel Wang, Magda Asselin, Diane Marie Joseph-McCarthy, Amarnauth Shastrie Prashad, Allan Wissner, Russell Dushin, Biqi Wu, Lawrence Nathan Tumey, Chuan S. Niu, Joan Chen
  • Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
    Patent number: 7732618
    Abstract: The invention relates to benzimidazole acetic acid compounds which function as antagonists of the Chemoattractant Receptor-homologous molecule expressed on T-Helper type 2 cells (CRTH2) receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: June 8, 2010
    Assignee: Wyeth
    Inventors: Youssef L. Bennani, Lawrence Nathan Tumey, Elizabeth Ann Gleason, Michael Joseph Robarge
  • INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF
    Publication number: 20100016389
    Abstract: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
    Type: Application
    Filed: September 24, 2009
    Publication date: January 21, 2010
    Applicant: Wyeth
    Inventors: Youssef L. Bennani, Lawrence Nathan Tumey, Elizabeth Ann Gleason, Michael Joseph Robarge
  • Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
    Patent number: 7601749
    Abstract: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: October 13, 2009
    Assignee: Wyeth
    Inventors: Youssef L. Bennani, Lawrence Nathan Tumey, Elizabeth Ann Gleason, Michael Joseph Robarge
  • INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF
    Publication number: 20090111867
    Abstract: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
    Type: Application
    Filed: December 16, 2008
    Publication date: April 30, 2009
    Applicant: Wyeth
    Inventors: Youssef L. Bennani, Lawrence Nathan Tumey, Elizabeth Ann Gleason, Michael Joseph Robarge
  • Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
    Patent number: 7476667
    Abstract: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: January 13, 2009
    Assignee: Wyeth
    Inventors: Youssef L. Bennani, Lawrence Nathan Tumey, Elizabeth Ann Gleason, Michael Joseph Robarge
  • INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF
    Publication number: 20080255100
    Abstract: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
    Type: Application
    Filed: June 2, 2008
    Publication date: October 16, 2008
    Applicant: Wyeth
    Inventors: Youssef L. Bennani, Lawrence Nathan Tumey, Elizabeth Ann Gleason, Michael Joseph Robarge
  • Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
    Patent number: 7405215
    Abstract: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: July 29, 2008
    Assignee: Wyeth
    Inventors: Youssef L. Bennani, Lawrence Nathan Tumey, Elizabeth Ann Gleason, Michael Joseph Robarge